The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. AACE President Scott D. Isaacs, MD, FACP, FACE, noted this major advancement highlights the urgency of expanding screening and implementing multidisciplinary care, as MASH remains highly prevalent and often underdiagnosed, particularly in people with diabetes and other cardiometabolic risk factors. Read the full article on Healio.